Ann: Presentation to Investors, page-100

Missed the presentation so if anyone could clarify the following points it would be much appreciated.

- we will be receiving the "headline results" for the phase II clinical trials, hopefully prior to the AGM in November.

- was the length of phase III discussed as the usual process with the FDA takes between 6-10 months of trials with large/mass groups of people and tested for efficiency against current drugs being used.

- was any company or organisation singled out during the presentation as an interested party or will that process start publicly after the results are released?

Thanks.